STAT+: Up and down the ladder: The latest comings and goings

STAT PlusPharmalot Up and down the ladder: The latest comings and goings Manage alerts for this article Email this article Share this article By Ed SilvermanMay 8, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week. This time around, we note that Immunic hired Michael Panzara as chief medical officer. Previously, he held the same position at Neurvati Neurosciences.Advertisement But all work and no play can make for a dull chief medical officer. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, jobs, Pharmaceuticals, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot May 8, 2026 STAT Plus: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and more Pharmalot May 7, 2026 STAT Plus: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more Advertisement Pharmalot May 6, 2026 STAT Plus: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more Pharmalot May 5, 2026 STAT Plus: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing Pharmalot May 5, 2026 STAT Plus: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more Subscriber Picks